免疫检查点抑制剂在肿瘤治疗中的研究进展
范广川

武汉大学药学院，湖北省武汉市，430072；

摘要：免疫检查点抑制剂自问世以来，凭借其对人体免疫系统的特殊激活作用，成功改善了临床肿瘤患者的生存率。但经典的免疫检查点抑制剂如PD-1抑制剂等，在临床使用过程中仍面临总体应答率偏低、耐药性不可避免等困境，且作用机制尚未完全揭示。本文通过对近年来各国学者发表的相关研究成果进行汇总整理，为解决上述问题提供参考策略，并对免疫检查点抑制剂的发展进行分析与展望。

关键词：免疫检查点抑制剂；耐药性；作用机制

参考文献

[1]Julie R Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, et al. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227[J]. Journal of Clinical Oncology,2023,41(6):1200-1212.

[2]Shixue Chen, Zhibo Zhang, Xuan Zheng. Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis[J]. Frontiers in Oncology,2021,11.

[3]Alessandro Inno, Giandomenico Roviello , Antonio Ghidini, et al. Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis[J]. Critical Reviews in Oncology / Hematology,2021,165.

[4]Guoshuang Shen, Zhilin Liu, Miaozhou Wang, et al. Neoadjuvant apatinib addition to sintilimab and carboplatintaxane based chemotherapy in patients with early triplenegative breast cancer: the phase 2 NeoSAC trial[J]. Signal Transduction and Targeted Therapy,2025,10:41.

[5]Jing Nie, Chunmeng Wang, Yang Liu, et al. Addition of Low-Dose Decitabine to Anti–PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma[J]. Journal of Clinical Oncology,2019,37(17):1479-1489.

[6]Willemijn S M E Theelen, Dawei Chen, Vivek Verma, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials[J]. The Lancet Respiratory Medicine,2020.

[7]Roy S. Herbst, Margarita Majem, Fabrice Barlesi, et al. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer[J]. Journal of Clinical Oncology, 2022,40(29):3383-3393.

[8]Jiachen Xu, Rui Wan, Yiran Cai, et al. Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer[J].Cancer Cell,2024,42:1598-1613.

[9]Hussein A. Tawbi, F. Stephen Hodi, Evan J. Lipson, et al. Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047[J].Journal of Clinical Oncology,2024.

[10]Tina Cascone, Gozde Kar, Jonathan D. Spicer, et al. Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial[J].Cancer Discovery,2023,13:2394-2411.